312 related articles for article (PubMed ID: 37880567)
1. Targeting ferroptosis in hepatocellular carcinoma.
Mo Y; Zou Z; Chen E
Hepatol Int; 2024 Feb; 18(1):32-49. PubMed ID: 37880567
[TBL] [Abstract][Full Text] [Related]
2. A Novel Ferroptosis-Related Long Non-Coding RNA Prognostic Signature Correlates With Genomic Heterogeneity, Immunosuppressive Phenotype, and Drug Sensitivity in Hepatocellular Carcinoma.
Li G; Liu Y; Zhang Y; Xu Y; Zhang J; Wei X; Zhang Z; Zhang C; Feng J; Li Q; Wang G
Front Immunol; 2022; 13():929089. PubMed ID: 35874689
[TBL] [Abstract][Full Text] [Related]
3. Ferroptosis Suppressor Protein 1 Inhibition Promotes Tumor Ferroptosis and Anti-tumor Immune Responses in Liver Cancer.
Cheu JW; Lee D; Li Q; Goh CC; Bao MH; Yuen VW; Zhang MS; Yang C; Chan CY; Tse AP; Sit GF; Liu CX; Ng IO; Wong CM; Wong CC
Cell Mol Gastroenterol Hepatol; 2023; 16(1):133-159. PubMed ID: 36893885
[TBL] [Abstract][Full Text] [Related]
4. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma.
Tang B; Zhu J; Li J; Fan K; Gao Y; Cheng S; Kong C; Zheng L; Wu F; Weng Q; Lu C; Ji J
Cell Commun Signal; 2020 Oct; 18(1):174. PubMed ID: 33115468
[TBL] [Abstract][Full Text] [Related]
5. Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis.
Yang R; Gao W; Wang Z; Jian H; Peng L; Yu X; Xue P; Peng W; Li K; Zeng P
Phytomedicine; 2024 Jan; 122():155135. PubMed ID: 37856990
[TBL] [Abstract][Full Text] [Related]
6. Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy.
Ajoolabady A; Tang D; Kroemer G; Ren J
Br J Cancer; 2023 Jan; 128(2):190-205. PubMed ID: 36229582
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
[TBL] [Abstract][Full Text] [Related]
8. Ferroptosis: a new promising target for hepatocellular carcinoma therapy.
Xu Q; Ren L; Ren N; Yang Y; Pan J; Zheng Y; Wang G
Mol Cell Biochem; 2023 Dec; ():. PubMed ID: 38051404
[TBL] [Abstract][Full Text] [Related]
9. Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review).
Liu RJ; Yu XD; Yan SS; Guo ZW; Zao XB; Zhang YS
Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757345
[TBL] [Abstract][Full Text] [Related]
10. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
Li J; Li Y; Wang D; Liao R; Wu Z
J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma.
Ou W; Mulik RS; Anwar A; McDonald JG; He X; Corbin IR
Free Radic Biol Med; 2017 Nov; 112():597-607. PubMed ID: 28893626
[TBL] [Abstract][Full Text] [Related]
12. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
[TBL] [Abstract][Full Text] [Related]
13. Targeting Ferroptosis-Elicited Inflammation Suppresses Hepatocellular Carcinoma Metastasis and Enhances Sorafenib Efficacy.
Mu M; Huang CX; Qu C; Li PL; Wu XN; Yao W; Shen C; Huang R; Wan CC; Jian ZW; Zheng L; Wu RQ; Lao XM; Kuang DM
Cancer Res; 2024 Mar; 84(6):841-854. PubMed ID: 38231484
[TBL] [Abstract][Full Text] [Related]
14. Iron accumulation and lipid peroxidation: implication of ferroptosis in hepatocellular carcinoma.
Li X; Meng F; Wang H; Sun L; Chang S; Li G; Chen F
Front Endocrinol (Lausanne); 2023; 14():1319969. PubMed ID: 38274225
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation.
Peleman C; Francque S; Berghe TV
EBioMedicine; 2024 Apr; 102():105088. PubMed ID: 38537604
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma.
Zhang L; Li XM; Shi XH; Ye K; Fu XL; Wang X; Guo SM; Ma JQ; Xu FF; Sun HM; Li QQ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2023 Mar; 44(3):622-634. PubMed ID: 36109580
[TBL] [Abstract][Full Text] [Related]
17. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive characterization of ferroptosis in hepatocellular carcinoma revealing the association with prognosis and tumor immune microenvironment.
Zhu J; Xu X; Jiang M; Yang F; Mei Y; Zhang X
Front Oncol; 2023; 13():1145380. PubMed ID: 37051544
[TBL] [Abstract][Full Text] [Related]
19. From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma.
Wang Z; Zhou C; Zhang Y; Tian X; Wang H; Wu J; Jiang S
Biomed Pharmacother; 2024 Jan; 170():116074. PubMed ID: 38147732
[TBL] [Abstract][Full Text] [Related]
20. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis.
Ren X; Li Y; Zhou Y; Hu W; Yang C; Jing Q; Zhou C; Wang X; Hu J; Wang L; Yang J; Wang H; Xu H; Li H; Tong X; Wang Y; Du J
Redox Biol; 2021 Oct; 46():102122. PubMed ID: 34482117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
